Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

4HPO

Crystal structure of RV144-elicited antibody CH58 in complex with V2 peptide

Summary for 4HPO
Entry DOI10.2210/pdb4hpo/pdb
Related4HPY 4HQQ
DescriptorCH58 Fab heavy chain, CH58 Fab light chain, Envelope glycoprotein gp160, ... (5 entities in total)
Functional Keywordsimmunoglobulin, immune system-viral protein complex, immune system/viral protein
Biological sourceHomo sapiens
More
Total number of polymer chains3
Total formula weight50906.62
Authors
McLellan, J.S.,Gorman, J.,Haynes, B.F.,Kwong, P.D. (deposition date: 2012-10-24, release date: 2013-02-06, Last modification date: 2023-09-20)
Primary citationLiao, H.X.,Bonsignori, M.,Alam, S.M.,McLellan, J.S.,Tomaras, G.D.,Moody, M.A.,Kozink, D.M.,Hwang, K.K.,Chen, X.,Tsao, C.Y.,Liu, P.,Lu, X.,Parks, R.J.,Montefiori, D.C.,Ferrari, G.,Pollara, J.,Rao, M.,Peachman, K.K.,Santra, S.,Letvin, N.L.,Karasavvas, N.,Yang, Z.Y.,Dai, K.,Pancera, M.,Gorman, J.,Wiehe, K.,Nicely, N.I.,Rerks-Ngarm, S.,Nitayaphan, S.,Kaewkungwal, J.,Pitisuttithum, P.,Tartaglia, J.,Sinangil, F.,Kim, J.H.,Michael, N.L.,Kepler, T.B.,Kwong, P.D.,Mascola, J.R.,Nabel, G.J.,Pinter, A.,Zolla-Pazner, S.,Haynes, B.F.
Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2.
Immunity, 38:176-186, 2013
Cited by
PubMed Abstract: The RV144 HIV-1 trial of the canary pox vector (ALVAC-HIV) plus the gp120 AIDSVAX B/E vaccine demonstrated an estimated efficacy of 31%, which correlated directly with antibodies to HIV-1 envelope variable regions 1 and 2 (V1-V2). Genetic analysis of trial viruses revealed increased vaccine efficacy against viruses matching the vaccine strain at V2 residue 169. Here, we isolated four V2 monoclonal antibodies from RV144 vaccinees that recognize residue 169, neutralize laboratory-adapted HIV-1, and mediate killing of field-isolate HIV-1-infected CD4(+) T cells. Crystal structures of two of the V2 antibodies demonstrated that residue 169 can exist within divergent helical and loop conformations, which contrasted dramatically with the β strand conformation previously observed with a broadly neutralizing antibody PG9. Thus, RV144 vaccine-induced immune pressure appears to target a region that may be both sequence variable and structurally polymorphic. Variation may signal sites of HIV-1 envelope vulnerability, providing vaccine designers with new options.
PubMed: 23313589
DOI: 10.1016/j.immuni.2012.11.011
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.694 Å)
Structure validation

227111

數據於2024-11-06公開中

PDB statisticsPDBj update infoContact PDBjnumon